Piramal Group

Mumbai, India Founded: 1984 • Age: 42 yrs Listed Fortune India 500 · #246
Multinational conglomerate with diverse interests in Pharma, Financial Services and Real Estate
Request Access
Report Incorrect Data
Page last updated

About Piramal Group

Piramal Group is a publicly listed company based in Mumbai (India) founded in 1984. Multinational conglomerate with diverse interests in Pharma, Financial Services and Real Estate. The company has 16,400 employees. Piramal Group has completed 8 acquisitions, including Ash Stevens, Biosyntech and Coldstream Labs. Its chief executive, as recorded, is Peter De Young. Its website piramal.com draws about 47 thousand monthly visits. Its Indian entity Piramal Pharma Limited reported revenue of ₹9,161 Cr. Piramal Group offers products and services including Housing Finance, Pharma Solutions, and Realty Development. Its focus areas include Biopharma Outsourcing, CDMO and Diversified. Its competitors include Syngene and Panacea Biotec; 1 of its 2 listed competitors has raised funding.

Company details

Founded in 1984 and headquartered in Mumbai, India, Piramal Group maintains a multinational presence across pharmaceuticals, healthcare services, life sciences, specialty glass packaging, and real estate sectors. Subsidiaries such as Piramal Healthcare, Piramal Capital, Decision Resources Group, Piramal Glass, Piramal Realty, and Piramal Foundation are included. Contract development and manufacturing solutions for first-in-class drugs, generics, and antibody drug conjugates are provided to pharma and biotech firms.

Piramal Group is ranked #246 on the Fortune India 500 (2025).

Recognitions & Rankings of Piramal Group

Fortune India 500 2025 edition
Rank#246
Total income
₹10,748 Cr
Profit
₹485 Cr
Last year #239
  • Headquarters Mumbai, India
  • Employees 16,400
  • Stage Public
  • Sectors
    Healthcare
  • Website category Health · Biotechnology and Pharmaceuticals
  • Email
    ••••••••
  • Phone
    •••• ••••
  • Website piramal.com
  • Social LinkedIn X Facebook
  • Legal Name Piramal Enterprises Ltd.
Operational Areas
Healthcare → Biopharma Outsourcing & Drug Delivery
Key Metrics
  • Market Cap
    ₹25,438 Cr

    PPLPHARMA · NSE

  • Share Price
    ₹195.17

    +2.15% today

  • Revenue
    ₹8,869 Cr

    FY 2025-26 · -3.1% YoY

  • EBITDA
    ₹704 Cr

    Margin 7.9%

  • Net Profit
    −₹312 Cr

    FY 2025-26 · -451.5% YoY

  • ROE
    -3.8%

    ROCE 2.5%

  • Debt / Equity
    0.65

    Interest cover -267.9x

  • Investors
    The Carlyle Group

    & 2 more

  • Employee Count
    16,400
  • Investments & Acquisitions
    Ash Stevens

    & 7 more

Products & Services of Piramal Group

Piramal Group offers a comprehensive portfolio of products and services, including Housing Finance, Pharma Solutions, and Realty Development.

Housing Finance
Financial Services

Provides loans and financing for housing needs

Pharma Solutions
Healthcare

Offers manufacturing and distribution of pharmaceutical products

Realty Development
Real Estate

Focuses on property development and community projects

Funding Insights of Piramal Group

  • Total Rounds 5
  • Investors Count 3

All 5 funding rounds of Piramal Group with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Jul 2020Post-IPO––
The Carlyle Group
Dec 2019$24.62MPost-IPO––
Caisse de depot et placement du Quebec
Oct 2019$250MPost-IPO––
Caisse de depot et placement du Quebec
Aug 2015$156.15MPost-IPO––
–
Jan 2011Grant––
Department of Biotechnology
Valuation history

3 investors in total: 3 institutional.

Investors in Piramal Group

Piramal Group has secured backing from 3 investors, including venture fund and institutional investors. Prominent investors backing the company include The Carlyle Group, Caisse de depot et placement du Quebec and Department of Biotechnology.

All
Venture Fund
Institutional
InvestorDescriptionFounded YearDomainLocation
Caisse de depot et placement du Quebec
Investment strategies are provided across diverse asset classes and markets.
1965cdpq.comQuebec City, Canada
The Carlyle Group
Private equity investments are directed toward multiple sectors.
1986carlyle.com
Department of Biotechnology
Biotechnology research, guidelines, and funding by the Government of India.
1986dbtindia.gov.inDelhi, India
Premium access

Investor details for Piramal Group

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

Board of directors of Piramal Pharma Limited (Piramal Group)

Piramal Pharma Limited is the primary company behind Piramal Group. The boards of the 6 registered companies of Piramal Group currently have 18 directors; the longest-serving is Sunilkumar Jagdishprasad Adukia, appointed in 2014. 40 earlier directors have ceased.

DirectorDesignationAppointedTenureEntity
Sunilkumar Jagdishprasad Adukia
DIN 00020049
Director27 Nov 201411 yrs 10 moPiramal Corporate Services Private Limited
Vandana Jitendra Chablani
DIN 03603877
Director14 Sep 201511 yrs 1 moPiramal Metals Private Limited, Piramal Natural Resources Private Limited
Kshitish Shreekant Bapat
DIN 07480212
Director17 Nov 20169 yrs 11 moBrickex Advisors Private Limited
Anand Ajay Piramal
DIN 00286085
Director13 Jun 20188 yrs 4 moPiramal Corporate Services Private Limited
Peter D Deyoung
DIN 07152550
Whole-time director04 Mar 20206 yrs 7 moPiramal Pharma Limited
Nandini Ajay Piramal
DIN 00286092
Whole-time director04 Mar 20206 yrs 7 moPiramal Pharma Limited
Ramadorai Subramanian
DIN 00000002
Director09 Feb 20215 yrs 8 moPiramal Pharma Limited
Jairaj Manohar Purandare
DIN 00159886
Director09 Feb 20215 yrs 8 moPiramal Pharma Limited
Sarita Shrinivas Iyer
DIN 07328713
Director23 Aug 20215 yrs 2 moPiramal Metals Private Limited, Piramal Natural Resources Private Limited
Vivek Valsaraj
DIN 06970246
Whole-time director09 Feb 20224 yrs 8 moPiramal Pharma Limited
Sridhar Gorthi
DIN 00035824
Director30 Mar 20224 yrs 6 moPiramal Pharma Limited
Peter Andrew Stevenson
DIN 09544706
Director30 Mar 20224 yrs 6 moPiramal Pharma Limited
Anuj Jitendra Mehta
DIN 00002922
Director12 Jul 20224 yrs 3 moBrickex Advisors Private Limited
Vibha Paul Rishi
DIN 05180796
Director30 Aug 20224 yrs 1 moPiramal Pharma Limited
Vaishali Jethwa
DIN 08937198
Designated Partner01 Aug 20233 yrs 2 moViridis Power Partners Llp
Bipin Singh
DIN 00058068
Designated Partner01 Aug 20233 yrs 2 moViridis Power Partners Llp
Nathalie Ann Leitch
DIN 09557042
Director28 Jan 20251 yr 8 moPiramal Pharma Limited
Amit Jain
DIN 06917608
Director14 May 20251 yr 5 moPiramal Pharma Limited

People of Piramal Group

94 people are tracked at Piramal Group (37 in leadership, 12 in board & advisors, 45 in team); the tracked headcount is 16,400.

NameRoleGroup
Peter De Young
CEOLeadership
Anand Ajay Piramal
CEO & Managing DirectorLeadership
Ajay Piramal
Chairman & Executive DirectorLeadership
Anand Piramal
Executive Director, Piramal GroupLeadership
Rupen Jhaveri
Group President, Piramal Enterprises LimitedLeadership
Pratik Upadhayay
Vice PresidentLeadership
Jairam Sridharan
Managing Director, Piramal Capital & Housing Finance LimitedLeadership
Lalit Ostwal
Head - Group TreasuryLeadership
Amol Pande
Associate General Manager-projectsLeadership
Yesh Nadkarni
CEO, Wholesale Lending, Piramal Capital & Housing Finance Ltd (PCHFL)Leadership
Upma Goel
CFO, Piramal Enterprises LimitedLeadership
Rajendra Mali
Vice President-head Manufacturing PCCLeadership
Harinder Sikka
Group DirectorLeadership
Ambrish Ajit Samant
Chief ManagerLeadership
Jatin Unadkat
Business Finance And BU HeadLeadership
Indushekhar Vora
Group President - Corporate ProjectsLeadership
Aakash Agrawal
Head Strategy And Chairman's Office - Piramal EnterprisesLeadership
Vaibhav Kulkarni
General Manager Information TechnologyLeadership
Mahendra Dhage
General Manager Corp. Projects, Piramal Healthcare Ltd.Leadership
Amit Goyal
General Manager FinanceLeadership

74 more people are available in the full profile.

Premium access

Complete people profiles for Piramal Group

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

IPO & Listings of Piramal Group

Piramal Group is a publicly listed company on the NSE with ticker symbol PPLPHARMA in India, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • IPO date19 Oct 2022
  • Listed onNSE: PPLPHARMA
  • Listed entityPiramal Pharma Limited
  • Exchange sectorHealth technology
  • Share price₹1,124.20 (+0.18% on the day) · 2025-09-29
  • Market capitalisation₹24,235 Cr
  • Price to earnings44.1
  • EPS (diluted, trailing year)₹25.47
  • Dividend yield0.98%
  • Volume (last session)2,148,582
  • Analyst consensusNeutral

Financials of Piramal Group

Exchange-reported figures of Piramal Pharma Limited, the listed company behind Piramal Group (NSE: PPLPHARMA).

Financial Highlights

FY 2025-26 · Consolidated
Revenue
₹8,869 Cr
-3.1% YoY
EBITDA
₹704 Cr
-51.3% YoY
Profit After Tax
−₹312 Cr
-451.5% YoY
Net Worth
₹8,163 Cr
+0.5% YoY
Total Assets
₹14,088 Cr
+6.7% YoY
Total Debt
₹5,675 Cr
+16.8% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Income statement
Revenue8,8699,1518,1717,0826,5596,315
Revenue growth-3.1%+12.0%+15.4%+8.0%+3.9%-
EBITDA7041,4451,1336219351,428
EBITDA margin+7.9%+15.8%+13.9%+8.8%+14.3%+22.6%
Profit before tax(176)415179(120)485949
Net profit(312)88.8215.83(186)384818
Net profit margin-3.5%+1.0%+0.2%-2.6%+5.9%+13.0%
EPS (₹)(2.46)0.690.13(1.56)3.178.40
Balance sheet
Total assets14,08813,20612,82212,61210,9918,780
Net worth8,1638,1257,9116,7746,6975,605
Total debt5,6754,8564,7105,6374,1283,025
Cash & bank1,224501483308329406
Net working capital3,5413,5543,0592,7172,4031,751
Cash flow
Cash from operations1,6538921,005484766598
Cash from investing(820)(488)(416)(1,334)(1,737)(4,464)
Cash from financing(38.98)(441)(422)8187943,977
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue2,2702,7522,1402,0441,9342,7542,2042,242
Revenue growth (YoY)+17.4%-0.1%-2.9%-8.8%-0.9%---
Other income10959.6353.5080.3997.7158.2529.1878.37
EBITDA195285155159107561338342
EBITDA margin+8.6%+10.3%+7.2%+7.8%+5.5%+20.4%+15.3%+15.2%
Depreciation224218213203197243197192
Interest88.0882.9989.2482.4286.15104103108
Profit before tax(7.46)43.00(93.86)(46.18)(79.02)27366.80120
Tax61.9351.8342.3353.042.6811963.1297.53
Net profit(69.39)(8.83)(136)(99.22)(81.70)1543.6822.59
EPS (₹)(0.52)(0.07)(1.03)(0.75)(0.62)1.160.030.17
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Income statement
Revenue4,7825,2864,3903,4433,3402,939
Revenue growth-9.5%+20.4%+27.5%+3.1%+13.7%-
EBITDA5491,04061890.57460619
EBITDA margin+11.5%+19.7%+14.1%+2.6%+13.8%+21.1%
Profit before tax877911508124462687
Net profit76868938872.64378556
Net profit margin+16.1%+13.0%+8.8%+2.1%+11.3%+18.9%
EPS (₹)5.275.222.960.583.105.75
Balance sheet
Total assets9,0228,7447,9216,9366,3004,281
Net worth8,1417,4536,7125,2625,1234,101
Total debt7861,2431,1771,6491,164174
Cash & bank57417824264.16137152
Net working capital1,8422,1011,7971,3371,166463
Cash flow
Cash from operations1,32854935871.5224934.72
Cash from investing(318)(552)(635)(435)(1,165)(4,383)
Cash from financing(615)(61.74)4512908964,494
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue1,1251,4891,1961,1279701,6901,2481,284
Revenue growth (YoY)+16.0%-11.9%-4.2%-12.2%-8.8%---
Other income11518496.1520218139.5124.70106
Total expenses1,0081,2511,0561,0009261,2731,0291,032
EBITDA11723814012744.33417219253
EBITDA margin+10.4%+16.0%+11.7%+11.3%+4.6%+24.7%+17.6%+19.7%
Depreciation65.7370.1264.6961.2559.4461.1755.4653.61
Interest16.3619.5016.8420.3823.2330.5629.1729.95
Profit before tax149332155247143364159276
Tax36.0070.2226.0251.0829.4487.0940.6165.65

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 26 Oct 2026
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue2,2702,7522,1402,0441,9342,7542,2042,242
Revenue growth (YoY)+17.4%-0.1%-2.9%-8.8%-0.9%---
Other income10959.6353.5080.3997.7158.2529.1878.37
EBITDA195285155159107561338342
EBITDA margin+8.6%+10.3%+7.2%+7.8%+5.5%+20.4%+15.3%+15.2%
Depreciation224218213203197243197192
Interest88.0882.9989.2482.4286.15104103108
Profit before tax(7.46)43.00(93.86)(46.18)(79.02)27366.80120
Tax61.9351.8342.3353.042.6811963.1297.53
Net profit(69.39)(8.83)(136)(99.22)(81.70)1543.6822.59
EPS (₹)(0.52)(0.07)(1.03)(0.75)(0.62)1.160.030.17
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Revenue8,8699,1518,1717,0826,5596,315
Revenue growth-3.1%+12.0%+15.4%+8.0%+3.9%-
Other income292208235279335230
Total expenses8,1657,7067,0386,4605,6254,887
Employee cost2,4162,3072,0301,8961,5891,468
EBITDA7041,4451,1336219351,428
EBITDA margin+7.9%+15.8%+13.9%+8.8%+14.3%+22.6%
Depreciation831816741677586545
Interest341422448344198163
Profit before tax(176)415179(120)485949
Tax15032416166.31109114
Net profit(312)88.8215.83(186)384818
Net profit margin-3.5%+1.0%+0.2%-2.6%+5.9%+13.0%
EPS (₹)(2.46)0.690.13(1.56)3.178.40
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Equity & liabilities
Share capital1,3271,3241,3231,1931,186995
Reserves & surplus6,8356,8016,5885,5805,5114,610
Shareholders' funds (net worth)8,1638,1257,9116,7746,6975,605
Minority interest0.000.000.000.000.000.00
Secured loans5,4704,5904,5365,4973,9812,601
Unsecured loans204266174140146424
Total debt5,6754,8564,7105,6374,1283,025
Total liabilities14,08813,20612,82212,61210,9918,780
Assets
Gross block14,82913,07712,09910,8429,5108,153
Net block8,6848,1337,9907,4696,8796,105
Capital work in progress1,1009771,1161,4191,172627
Investments437291385639267123
Inventories3,0642,3132,1761,6811,3891,232
Sundry debtors2,1582,3502,1341,7991,7851,575
Cash & bank balances1,224501483308329406
Loans & advances614614527620514436
Total current assets7,0605,7775,3204,4084,0173,649
Total current liabilities3,5192,2232,2611,6911,6141,898
Net working capital3,5413,5543,0592,7172,4031,751
Total assets14,08813,20612,82212,61210,9918,780
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Opening cash18221953.2385.18262152
Net cash from operating activities1,6538921,005484766598
Net cash from investing activities(820)(488)(416)(1,334)(1,737)(4,464)
Net cash from financing activities(38.98)(441)(422)8187943,977
Net change in cash794(36.87)166(31.95)(177)110
Closing cash1,224501483308329406
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Growth
Sales growth-3.1%+12.0%+15.4%+8.0%+3.9%-
EBITDA growth-51.3%+27.5%+82.4%-33.5%-34.6%-
PBT growth-+131.3%+9998.0%--48.9%+9997.0%
Net income growth-451.5%+461.1%+108.5%-148.4%-53.0%-
Revenue CAGR (3Y)+7.8%+11.7%+9.0%---
EBITDA CAGR (3Y)+4.3%+15.6%-7.4%---
Profitability & leverage
Net income margin-3.7%+1.0%+0.2%-2.6%+5.7%+13.2%
Return on capital employed+2.5%+6.4%+5.4%+1.9%+6.9%+12.7%
Return on net worth-3.8%+1.1%+0.2%-2.8%+6.1%+14.9%
Debt / equity0.650.600.700.720.580.54
Long-term debt / equity0.480.370.410.460.420.43
Interest cover-267.9567.08114.15-621.1556.9018.51
Efficiency & per share
Fixed asset turnover0.640.730.710.700.740.77
Inventory turnover3.304.084.244.615.015.13
Debtors turnover3.944.084.153.953.904.01
EPS (₹)(2.46)0.690.13(1.56)3.178.40
Dividend per share (₹)0.000.140.110.000.560.00
Book value per share (₹)61.5061.3559.8056.7656.4756.35
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue1,1251,4891,1961,1279701,6901,2481,284
Revenue growth (YoY)+16.0%-11.9%-4.2%-12.2%-8.8%---
Other income11518496.1520218139.5124.70106
Total expenses1,0081,2511,0561,0009261,2731,0291,032
EBITDA11723814012744.33417219253
EBITDA margin+10.4%+16.0%+11.7%+11.3%+4.6%+24.7%+17.6%+19.7%
Depreciation65.7370.1264.6961.2559.4461.1755.4653.61
Interest16.3619.5016.8420.3823.2330.5629.1729.95
Profit before tax149332155247143364159276
Tax36.0070.2226.0251.0829.4487.0940.6165.65
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Revenue4,7825,2864,3903,4433,3402,939
Revenue growth-9.5%+20.4%+27.5%+3.1%+13.7%-
Other income663207202341225216
Total expenses4,2334,2453,7723,3532,8802,320
Employee cost745736614548448395
EBITDA5491,04061890.57460619
EBITDA margin+11.5%+19.7%+14.1%+2.6%+13.8%+21.1%
Depreciation256222205192165144
Interest79.9511510711657.294.71
Profit before tax877911508124462687
Tax17722011654.1994.79115
Net profit76868938872.64378556
Net profit margin+16.1%+13.0%+8.8%+2.1%+11.3%+18.9%
EPS (₹)5.275.222.960.583.105.75
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Equity & liabilities
Share capital1,3271,3241,3231,1931,186995
Reserves & surplus6,8146,1285,3894,0683,9373,106
Shareholders' funds (net worth)8,1417,4536,7125,2625,1234,101
Secured loans4211,0098961,3131,15490.20
Unsecured loans36523428133610.6984.06
Total debt7861,2431,1771,6491,164174
Total liabilities9,0228,7447,9216,9366,3004,281
Assets
Gross block4,5754,2493,7673,5653,2252,260
Net block3,0362,8942,6122,6022,4391,627
Capital work in progress221327533417405121
Investments3,5803,1051,7081,7471,6301,592
Inventories1,8731,2051,153819536421
Sundry debtors1,4061,6671,331910989840
Cash & bank balances57417824264.16137152
Loans & advances451486504456403355
Total current assets4,3053,5363,2302,2492,0651,768
Total current liabilities2,4621,4341,4339128991,305
Net working capital1,8422,1011,7971,3371,166463
Total assets9,0228,7447,9216,9366,3004,281
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Opening cash16422954.281281470.74
Net cash from operating activities1,32854935871.5224934.72
Net cash from investing activities(318)(552)(635)(435)(1,165)(4,383)
Net cash from financing activities(615)(61.74)4512908964,494
Net change in cash395(64.93)175(73.41)(19.03)146
Closing cash57417824264.16137152
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Growth
Sales growth-9.5%+20.4%+27.5%+3.1%+13.7%-
EBITDA growth-47.2%+68.4%+582.3%-80.3%-25.7%-
PBT growth-3.8%+79.5%+310.4%-73.3%-32.7%+9997.0%
Net income growth+11.4%+77.6%+434.0%-80.8%-32.0%-
Revenue CAGR (3Y)+11.6%+16.5%+14.3%---
EBITDA CAGR (3Y)+82.4%+31.3%-0.1%---
Profitability & leverage
Net income margin+14.6%+13.1%+8.9%+2.0%+11.0%+19.5%
Return on capital employed+10.8%+12.3%+8.3%+3.6%+9.8%+16.2%
Return on net worth+9.0%+9.8%+6.5%+1.3%+8.0%+13.9%
Debt / equity0.130.170.240.270.150.04
Long-term debt / equity0.050.050.080.110.050.00
Interest cover27.1914.0025.95-114.1519.430.99
Efficiency & per share
Fixed asset turnover1.081.321.201.011.221.30
Inventory turnover3.114.484.455.096.996.98
Debtors turnover3.113.533.923.633.653.50
EPS (₹)5.275.222.960.583.105.75
Dividend per share (₹)0.000.140.110.000.560.00
Book value per share (₹)61.3456.2750.7444.0943.2041.23

Investments & Acquisitions by Piramal Group

Piramal Group has strategically engaged in corporate development activities, having acquired 8 companies. Notable acquisitions include Ash Stevens, Biosyntech and Coldstream Labs.

Acquisitions
Company NameDescriptionDomainLocationFoundedAcquiredAmount
Deewan Housing Finance Corporation
Provider of diversified financial services
dhfl.comMumbai, India1984Jan 2021$5.19B
Goyal & Co
Real estate builders and developers offering residential and commercial properties
goyalco.comAhmedabad, India1971May 2018••••
Ash Stevens
Small-molecule drug development and cGMP manufacturing services are offered.
ashstevens.comRiverview, United States1962Aug 2016$42.95M
HealthHiway
Care coordination solutions for healthcare organizations
healthhiway.comHyderabad, India2007Apr 2015••••
Coldstream Labs
Formulation development and contract manufacturing services are provided in pharmaceuticals.
coldstreamlabs.comLexington, United States2007Jan 2015$30.65M
Decision Resources Group
Healthcare research and consulting are delivered via business intelligence platforms.
decisionresourcesgroup.comBurlington, United States1995May 2012$650M
Biosyntech
Biotherapeutic thermogels are developed for tissue repair applications.
biosyntech.comLaval, Canada1994Jun 2010$3.83M
Minrad
A single-use device used to obtain biopsies of bone
minrad.comBuffalo, United States2005Jan 2009$40M
Premium access

Complete acquisition details for Piramal Group

Acquired stakes, deal sources and the complete acquisition history require an active premium plan.

  • Acquired stakes
  • Deal sources
  • Complete history
  • Exports

Verified entity values are shown only after access is granted.

Timeline of Piramal Group

12 dated milestones of Piramal Group across 38 years, from founding to its latest funding, stage changes and deals.

  1. Founded Piramal Group is founded.
  2. Acquisition Acquires Minrad.
  3. Acquisition Acquires Biosyntech.
  4. Funding First funding round.
  5. Acquisition Acquires Decision Resources Group.
  6. Acquisition Acquires Coldstream Labs.
  7. Acquisition Acquires HealthHiway.
  8. Acquisition Acquires Ash Stevens.
  9. Acquisition Acquires Goyal & Co.
  10. Funding Latest funding round, Post-IPO,.
  11. Acquisition Acquires Deewan Housing Finance Corporation.
  12. IPO Lists on the stock exchange (IPO).

Competitors of Piramal Group

Piramal Group has 2 listed competitors in our database, 1 of them funded. They include Syngene and Panacea Biotec.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
Syngene
syngeneintl.com1993Bengaluru, India$85.89M5,618
Provider of contract research and manufacturing services for both small molecules and biologics
Panacea Biotec
panaceabiotec.com1984Ambala, India2,095
Developer of biosimilars, vaccines and natural products
Premium access

Detailed competitors of Piramal Group

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Web traffic of Piramal Group

The website of Piramal Group (piramal.com) receives about 47K visits a month and ranks #586,886 among all websites worldwide, #613 in Biotechnology and Pharmaceuticals.

  • Monthly visits
    47K

    ▲ 13.4% vs previous month

  • Unique visitors
    17.9K

    per month

  • Global rank
    #586,886

    among all websites

  • Category rank
    #613

    Health · Biotechnology and Pharmaceuticals

Similar websites

Websites whose visitors overlap most with Piramal Group. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
Piramal Enterprises
piramalenterprises.com
100%
6.6K#2,681,887View details
Piramal Pharma Solutions
piramalpharmasolutions.com
90%
15.7KView details
Aspen Pharmacare
aspenpharma.com
63%
50.4K#657,613View details
panacea-biotec.com
panacea-biotec.com
45%
–
Cipla
cipla.com
44%
200.9K#203,362View details
••••••••••••••••.com••%•.•M#•••••–
••••••••••••••••.com••%•.•M#•••••–
••••••••••••••••.com••%•.•M#•••••–
Premium access

All 12 similar websites and full traffic analytics for Piramal Group

The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.

  • 12 similar websites
  • Audience overlap
  • Engagement analytics
  • Traffic by brand

Verified entity values are shown only after access is granted.

Top companies in Biopharma Outsourcing & Drug Delivery

3 companies that operate in the same segment as Piramal Group (Biopharma Outsourcing & Drug Delivery) in India, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
Anthem Biosciences
Developer of integrated contract research development and manufacturing services
2007Bengaluru, Karnataka, IndiaUSD 35.74 MUSD 226.38 M1,820
Laurus Labs
Pharmaceutical and biotechnology company
2005Hyderabad, Telangana, IndiaUSD 229.73 MUSD 726.15 M12,470
Entero Healthcare
India's leading healthcare products distribution platform
2018Mumbai, Maharashtra, IndiaUSD 59.67 MUSD 702.49 M4,260
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • ✓
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • ✓
    Full access to every database India & global coverage, advanced filters and rich profile details
  • ✓
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Piramal Group

Piramal Pharma Solutions Opens New Microbiology Lab in Kentucky to Boost Sterility Testing Capabilities
Contract Pharma • 19 days ago
Piramal Pharma Solutions Launches New Microbiology Laboratory at Its Lexington, KY Sterile Injectable Facility
Business Standard • 20 days ago
Piramal Pharma Solutions Launches New Microbiology Laboratory at Its Lexington, KY Sterile Injectable Facility - The Wire
The Wire • 20 days ago
Piramal Pharma Solutions Launches New Microbiology Laboratory at Lexington Facility
WebDisclosure • 20 days ago
Piramal Pharma Solutions and NP2 to Complete Cyclophosphamide Development Phase Next Month - The Wire
The Wire • 25 days ago
Piramal Pharma Solutions and NP2 to Complete Cyclophosphamide Development Phase Next Month
Business Standard • 25 days ago
Piramal Pharma Solutions receives $1.75M from Ontario to boost life sciences innovation at Aurora facility
PR Newswire • 25 days ago
Piramal Pharma Solutions' Aurora site receives CAD 1.75M from Ontario's Life Sciences Scale-Up Fund
PR Newswire • 25 days ago
Piramal Pharma: Sales Deal With Bayer Pharmaceuticals Ends December 31, 2026, Without Renewal.
Exchange Update • 25 days ago
Ontario Contributes $1.7 Million to Advance Life Sciences Innovation at Piramal Pharma's Aurora Facility
CNW • 26 days ago
Premium access

Complete news archive for Piramal Group

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Piramal Group

Piramal Group was founded in 1984 and raised its 1st funding round 27 years after it was founded.

Piramal Group is headquartered in Mumbai, India. It is registered at Mumbai, Maharashtra, India.

Peter De Young is the CEO of Piramal Group, as recorded in our data.

Piramal Group has 16,400 employees.

The primary company behind Piramal Group, Piramal Pharma Limited, reported revenue of ₹9,161 Cr for FY 2026, down 3% year on year.

Founded in 1984 and headquartered in Mumbai, India, Piramal Group maintains a multinational presence across pharmaceuticals, healthcare services, life sciences, specialty glass packaging, and real estate sectors. Subsidiaries such as Piramal Healthcare, Piramal Capital, Decision Resources Group, Piramal Glass, Piramal Realty, and Piramal Foundation are included. Contract development and manufacturing solutions for first-in-class drugs, generics, and antibody drug conjugates are provided to pharma and biotech firms.

Piramal Group's top competitors include Syngene and Panacea Biotec.

Piramal Group offers Housing Finance, Pharma Solutions, and Realty Development.

Yes, Piramal Group is publicly traded on NSE under the ticker symbol PPLPHARMA.

Piramal Group has made 8 acquisitions, including Ash Stevens, Biosyntech, and Coldstream Labs.

Piramal Group has 3 investors. Key investors include The Carlyle Group, Caisse de depot et placement du Quebec, and Department of Biotechnology.

Piramal Group is associated with 6 legal entities: Piramal Pharma Limited, Viridis Power Partners Llp, Piramal Metals Private Limited and others.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available